Cover Image
市場調查報告書

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF) :開發中產品分析

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 363578
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF) :開發中產品分析 Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 80 Pages
簡介

本報告提供顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF)的概要

治療藥的開發

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中的產品 - 各開發階段

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中的產品 - 各治療範圍

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中的產品 - 各適應症

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):企業開發中的產品

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):大學/機關開發中的產品

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF)的治療藥的開發企業

  • Aduro BioTech, Inc.
  • Amgen Inc.
  • BriaCell Therapeutics Corp.
  • GlaxoSmithKline Plc
  • Humabs BioMed SA
  • KaloBios Pharmaceuticals, Inc.
  • Morphotek, Inc.
  • Sillajen Biotherapeutics
  • 武田藥品工業

藥物簡介

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):暫停中的計劃

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):開發中止的產品

顆粒球巨噬細胞細胞聚落刺激因子 (GM-CSF):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0775TDB

Summary

According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2017'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.

The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2017' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System and Respiratory which include indications Rheumatoid Arthritis, Breast Cancer, Melanoma, Solid Tumor, Hepatocellular Carcinoma, Multiple Sclerosis, Muscle Invasive Bladder Cancer (MIBC), Pancreatic Cancer, Soft Tissue Sarcoma, Bone Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colon Carcinoma, Juvenile Myelomonocytic Leukemia (JMML), Leukemias, Liver Cancer, Lung Adenocarcinoma, Lung Disease, Lymphoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Melanoma, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Osteoarthritis Pain, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Renal Cell Carcinoma and Squamous Cell Carcinoma.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
  • The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)targeted therapeutics and enlists all their major and minor projects
  • The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Overview
    • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Companies Involved in Therapeutics Development
    • Aduro BioTech Inc
    • Amgen Inc
    • BriaCell Therapeutics Corp
    • Cold Genesys Inc
    • GlaxoSmithKline Plc
    • Humabs BioMed SA
    • KaloBios Pharmaceuticals Inc
    • Morphotek Inc
    • Sillajen Biotherapeutics
    • Takeda Pharmaceutical Company Ltd
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Drug Profiles
    • CG-0070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG0070 + Immune Checkpoint Modulator - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gimsilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3196165 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenzilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • namilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OrienX-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pexastimogene devacirepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STINGVAX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVBR-1GM - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • talimogene laherparepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Dormant Products
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Discontinued Products
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Product Development Milestones
    • Featured News & Press Releases
      • May 15, 2017: Cold Genesys Announces Clinical Results at American Urological Association Annual Meeting 2017
      • May 08, 2017: Scottish Medicines Consortium Rejects Imlygic For Use Within NHS Scotland
      • May 08, 2017: BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax in Advanced Breast Cancer
      • Apr 25, 2017: Cold Genesys Announces Acceptance of Late Breaking Abstract at American Urological Association (AUA) Annual Meeting 2017
      • Apr 24, 2017: SillaJen And Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial For Pexa-Vec in Advanced Liver Cancer
      • Apr 12, 2017: Transgene and Institut Bergonie Start the Phase 2 Part of the METROmaJX Trial
      • Mar 15, 2017: BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax in Patients with Advanced Breast Cancer
      • Mar 07, 2017: BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms
      • Feb 06, 2017: BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax in Advanced Breast Cancer
      • Dec 05, 2016: BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory
      • Nov 29, 2016: Kalobios To Present At JMML International Symposium
      • Nov 29, 2016: BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax
      • Nov 10, 2016: BriaCell Provides Clinical Development Update on BriaVax
      • Oct 26, 2016: BriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director
      • Oct 06, 2016: Talimogene laherparepvec in melanoma: Added benefit not proven
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Aduro BioTech Inc, H1 2017
  • Pipeline by Amgen Inc, H1 2017
  • Pipeline by BriaCell Therapeutics Corp, H1 2017
  • Pipeline by Cold Genesys Inc, H1 2017
  • Pipeline by GlaxoSmithKline Plc, H1 2017
  • Pipeline by Humabs BioMed SA, H1 2017
  • Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
  • Pipeline by Morphotek Inc, H1 2017
  • Pipeline by Sillajen Biotherapeutics, H1 2017
  • Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Dormant Products, H1 2017
  • Dormant Products, H1 2017 (Contd..1), H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top